T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …

The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

Cancer immunotherapy using T cell receptor-engineered T cells (TCR-Ts) represents a
promising treatment option. However, technologies for pre-clinical safety assessment are …

The recognition of antigenic peptide-MHC (pMHC) molecules by T-cell receptors (TCR)
initiates the T-cell mediated immune response. Structural characterization is key for …

Materno-fetal immunity possesses specialized characteristics to ensure pathogen clearance
while maintaining tolerance to the semiallogeneic fetus. Most of our understanding on …

pHLA complexes represent the largest class of cell surface markers on cancer cells, making
them attractive for targeted cancer therapies. Adoptive cell therapies expressing TCRs that …

Generation of high avidity T cell receptors (TCRs) reactive to tumor-associated antigens
(TAA) is impaired by tolerance mechanisms, which is an obstacle to effective T cell therapies …

The prediction of major histocompatibility complex (MHC)-peptide binding affinity is an
important branch in immune bioinformatics, especially helpful in accelerating the design of …

Transgenic mice expressing human major histocompatibility complex class II (MHCII) risk
alleles are widely used in autoimmune disease research, but limitations arise due to non …

Assessment of immune-cell subsets within the tumor immune microenvironment is a
powerful approach to better understand cancer immunotherapy responses. However, the …